Renin Inhibitors

Hypertension

Volumn , Issue , 2005, Pages 754-764

  Nussberger, Jürg ^a,b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 36448969875     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7216-0258-5.50162-9     Document Type: Chapter

References (63)

1. Tigerstedt R, Bergman PG Niere und Kreislauf. Skand Arch Physiol 1898, 8:223-271.
2. Mazzolai L, Pedrazzini T, Nicoud F, et al. Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice. Hypertension 2000, 35:985-991.
3. Brunner HR, Gavras H, Laragh JH, et al. Angiotensin II blockade in man by sar1-ala8-angiotensin II for understanding and treatment of high blood pressure. Lancet 1973, ii:1045-1048.
4. Christen Y, Waeber B, Nussberger J, et al. Oral administration of DuP753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressure response to exogenous angiotensin I and II. Circulation 1991, 83:1333-1342.
5. Bühler FR, Laragh JH, Vaughan ED, et al. Antihypertensive action of propranolol: Specific anti-renin responses in high and normal renin forms of essential, renal, renovascular and malignant hypertension. Am J Cardiol 1973, 32:511-522.
6. Michelakis AM, McAllister RG The effect of chronic adrenergic receptor blockade on plasma renin activity in man. J Clin Endocrinol Metab 1972, 34:386-394.
7. Nussberger J Circulating versus tissue angiotensin II. Angiotensin II Receptor Antagonists 2000, 69-78. Hanley and Belfus, Philadelphia. M. Epstein, H.R. Brunner (Eds.).
8. Juillerat L, Nussberger J, Ménard J, et al. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension 1990, 16:564-572.
9. Kokubu T, Ueda E, Fujimoto S, et al. Peptide inhibitors of the renin-angiotensin system. Nature 1968, 217:456-457.
10. Poulsen K, Burton J, Haber E Competitive inhibitors of renin: A review. Prog Biochem Pharmacol 1976, 12:135-141.
11. Haber E Specific inhibitors of renin. Clin Sci 1980, 59(Suppl 6):7-19.
12. Zusman RM, Burton J, Christensen D, et al. Hemodynamic effects of a competitive renin in inhibitory peptide in humans. Evidence for multiple mechanisms of action. Trans Assoc Am Physicians 1983, 96:365-374.
13. Pals DT, DeGraaf DL, Kari WM, et al. Cardiovascular effects of a renin inhibitor in relation to posture in nonhuman primates. Clin Exp Hypertens A 1985, 7:105-121.
14. Waeber B, Nussberger J, Brunner HR Angiotensin-converting enzyme inhibitors in hypertension. Hypertension: Pathophysiology, Diagnosis and Management 1995, 2861-2875. Raven Press, New York. J.H. Laragh, B.M. Brenner (Eds.).
15. Ferreira SH A bradykinin-potentiating factor present in the venom of Bothrops jararaca. Br J Pharmacol 1965, 24:163-169.
16. Ferreira SH, Greene X Isolation of bradykinin-potentiating peptides from Bothrops jararaca venom. Biochemistry 1970, 9:2583-2593.
17. Cushman DW, Ondetti MA Inhibitors of angiotensin converting enzyme. Prog Med Chem 1980, 17:41-104.
18. Bohlender J, Nussberger J, Bader M, et al. Feedback-control of renin and angiotensin levels in rats transgenic for wild-type angiotensinogen. Hypertension, submitted.
19. Azizi M, Bissery A, Bura-Rivière A, et al. Dual renin-angiotensin system blockade restores blood pressure-renin dependency in individuals with low renin concentrations. J Hypertens 2003, 21:1887-1895.
20. Oparil S, Haber E The renin-angiotensin system. N Engl J Med 1974, 291:389-401.
21. Dzau V, Kopelman RI, Barger AC, et al. Comparison of renin-specific IgG and antibody fragment in studies of blood pressure regulation. Am J Physiol 1984, 246:H404-H409 and 247:XXXII.
22. Michel JB, Galen FX, Guettier C, et al. Immunological approach to blockade of the renin-substrate reaction. J Hypertens 1989, 7(Suppl 2):S63-S70.
23. Johnson CA, Wakerlin GE Antiserum for renin. Proc Soc Exp Biol Med 1940, 44:277-281.
24. Gross F, Lazar J, Orth H Inhibition of the renin-angiotensino-gen reaction by pepstatin. Science 1972, 175:656.
25. Evin G, Gardes J, Kreft C, et al. Soluble pepstatins: A new approach to blockade in vivo of the renin angiotensin system. Clin Sci 1978, 55:167s-171s.
26. Eid M, Evin G, Castro B, et al. New renin inhibitors homologous with pepstatin. Biochem J 1981, 197:465-471.
27. Boger J, Lohr NS, Ulm EH, et al. Novel renin inhibitors containing the amino acid statine. Nature 1983, 303:81-84.
28. Hui K, Haber E Renin inhibitors. The Renin-Angiotensin System 1993, 85.1-85.14. Raven Press, New York. J.I.S. Robertson, M.G. Nicholls (Eds.).
29. Skeggs LT, Lentz KE, Kahn JR, et al. Kinetics of the action of renin with nine synthetic peptide substrates. J Exp Med 1968, 128:13-34.
30. Tewksbury DA, Dart RA, Travis J The amino terminal amino acid sequence of human angiotensinogen. Biochem Biophys Res Commun 1981, 99:1311-1315.
31. Poulsen K, Burton J, Haber E Competitive inhibitors of renin. Biochemistry 1973, 12:3877-3882.
32. Burton J, Poulsen K, Haber E Competitive inhibitors of renin. Inhibitors effective at physiological pH. Biochemistry 1975, 14:3892-3898.
33. Haber E Peptide inhibitors of renin in cardiovascular studies. Fed Proc 1983, 42:3155-3161.
34. Burton J, Cody RJ, Herd JA, et al. Specific inhibition of renin by an angiotensinogen analog: Studies in sodium depletion and renin-dependent hypertension. Proc Natl Acad Sci USA 1980, 77:5476-5479.
35. Evin G, Devin J, Castro B, et al. Synthesis of peptides related to the prosegment of mouse submaxillary gland renin precursor: A new approach to renin inhibitors. Proc Natl Acad Sci USA 1984, 81:48-52.
36. Cumin F, Evin G, Fehrentz JA, et al. Inhibition of human renin by synthetic peptides derived from its prosegment. J Biol Chem 1985, 260:9154-9157.
37. James MNG, Sielecki A, Salituro F, et al. Conformational flexibility in the active site of aspartyl proteinases revealed by a pepstatin fragment binding to penicillopepsin. Proc Natl Acad Sci USA 1982, 79:6137-6141.
38. Szelke M, Leckie B, Hallett A, et al. Potent new inhibitors of human renin. Nature 1982, 299:555-557.
39. Webb DJ, Manhem PJO, Ball SG, et al. A study of the renin inhibitor H142 in man. J Hypertens 1985, 3:653-658.
40. Luly JR, BaMaung N, Soderquist J, et al. Renin inhibitors. Dipeptide analogues of angiotensinogen utilizing a dihydrox-yethylene transition-state mimic at the scissile bond to impart greater inhibitory potency. J Med Chem 1988, 31:2264-2276.
41. Wood JM, Gulati N, Forgiarini P, et al. Effects of a specific and long-acting renin inhibitor in the marmoset. Hypertension 1985, 7:797-803.
42. Toda N, Miyazaki M, Etoh Y, et al. Human renin inhibiting dipeptide. Eur J Pharmacol 1986, 129:393-396.
43. Hanson GJ, Baran JS, Lowrie HS, et al. Dipeptide glycols: A new class of renin inhibitors. Biochem Biophys Res Commun 1985, 132:155-161.
44. Nussberger J, Brunner D, Waeber B, et al. True versus immunoreactive angiotensin II in human plasma. Hypertension 1985, 7(Suppl I):I1-I7.
45. Nussberger J, Brunner HR Measurement of angiotensins in plasma. The Renin-Angiotensin System 1993, 15.1-15.13. Raven Press, New York. J.I.S. Robertson, M.G. Nicholls (Eds.).
46. Jeunemaître X, Ménard J, Nussberger J, et al. Plasma angiotensins, renin and blood pressure during acute renin inhibition by CGP 38560A in hypertensive patients. Am J Hypertens 1989, 2:819-827.
47. Hui KY, Knight DR, Nussberger J, et al. Effects of renin inhibition in the conscious primate Macaca fascicularis. Hypertension 1989, 14:480-487.
48. Fitzpatrick MA, Rademaker MT, Charles CJ, et al. Comparison of the effect of renin inhibition and angiotensin-converting enzyme inhibition in ovine heart failure. J Cardiovasc Pharmacol 1992, 19:169-175.
49. Blaine E, Schorn T, Boger J Statine-containing renin inhibitor: Dissociation of blood pressure lowering and renin inhibition in sodium-deficient dogs. Hypertension 1984, 6(Suppl I):I111-I118.
50. Nussberger J, Brunner D, Waeber B, et al. In vitro renin inhibition to prevent generation of angiotensins during determination of plasma angiotensin I and II. Life Sci 1988, 42:1683-1688.
51. Haber E, Koerner T, Page LB, et al. Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J Clin Endocrinol Metab 1969, 29:1349-1355.
52. Sealey JE, Gerten-Banes J, Laragh JH The renin system. Variations in man measured by radioimmunoassay or bioassay Kidney Int 1972, 1:240-253.
53. Poulsen K, Joergensen J An easy radioimmunological microas-say of renin activity, concentration and substrate in human and animal plasma and tissues based on angiotensin I trapping by antibody. J Clin Endocrinol Metab 1974, 39:816-825.
54. Camenzind E, Nussberger J, Juillerat L, et al. Effect of the renin response during renin inhibition: Oral Ro 42-5892 in normal humans. J Cardiovasc Pharmacol 1991, 18:299-307.
55. Weber MA, Neutel JM, Essinger I, et al. Assessment of renin dependency of hypertension with a dipeptide renin inhibitor. Circulation 1990, 61:1768-1774.
56. Delabays A, Nussberger J, Porchet M, et al. Hemodynamic and humoral effects of the new renin inhibitor enalkiren in normal humans. Hypertension 1989, 13:941-947.
57. Nussberger J, Delabays A, de Gasparo M, et al. Hemodynamic and biochemical consequences of renin inhibition by infusion of CGP 38560A in normal volunteers. Hypertension 1989, 13:948-953.
58. Van den Meiracker AH, Admiraal PJJ, Man in't Veld AJ, et al. Prolonged blood pressure reduction by orally active renin inhibitor RO-42-5892 in essential hypertension. Br Med J 1990, 301:205-210.
59. Zusman RM, Hui KY, Nussberger J, et al. R-PEP-27, a potent renin inhibitor, decreases plasma angiotensin II and blood pressure in normal volunteers. Am J Hypertens 1994, 7:295-301.
60. Boger RS, Glassman HN, Thys R, et al. Absorption and blood pressure response to the new orally active renin inhibitor, A-72517, in hypertensive patients. Am J Hypertens 1993, 6:103A.
61. Ogihara T, Nagano M, Higaki J, et al. Antihypertensive efficacy of FK 906, a novel human renin inhibitor. Clin Ther 1993, 15:539-548.
62. Nussberger J, Wuerzner G, Jensen C, et al. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100). Hypertension 2002, 39:e1-e8.
63. Stanton A, Jensen C, Nussberger J, et al. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003, 42:1137-1143.